Authorized health care providers should now order the monoclonal antibody therapy bamlanivimab and antibody cocktail casirivimab/imdevimab directly from the sole distributor, AmerisourceBergen Corp., the Department of Health and Human Services announced Friday.

HHS’ Office of the Assistant Secretary for Preparedness and Response will no longer allocate the therapies to health departments because the drugs are no longer in short supply, the agency said, noting that the products remain free of charge to requesting sites. “HHS will continue to monitor all direct orders, and we retain the capacity to resume allocation of these and future therapies if needed.” For more on the direct ordering process, see the ASPR guide.

The Food and Drug Administration in November issued emergency use authorizations for bamlanivimab and casirivimab/imdevimab to treat certain COVID-19 outpatients at risk for severe disease.

Related News Articles

Blog
The American Hospital Association and its Society for Healthcare Strategy and Market Development (SHSMD) July 15 hosted “Addressing COVID-19 Vaccine Hesitancy…
Headline
Read a recap and insights from health care leaders during AHA’s July 15 webinar, “Addressing COVID-19 Vaccine Hesitancy in Your Community,” featuring messaging…
Headline
Three-quarters of the 469 COVID-19 cases associated with summer events and large public gatherings this month in Barnstable County, Mass., were in people fully…
Headline
About 8.9 million children aged 12-17 have received the Pfizer COVID-19 vaccine, the Centers for Disease Control and Prevention reported today. Based on data…
Headline
AHA today joined 27 other organizations that serve the mental, emotional and behavioral health of children in urging Congress to strengthen the pediatric…
Perspective
The COVID-19 Provider Relief Fund has been a lifeline for hospitals, health systems and health care providers, allowing them to continue to put the health and…